US EditionRongchang Biopharma's Phase Iii Clinical Study of Tetasip for the Treatment of Primary Sjögren's Syndrome Reached Its Primary Endpoint
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
YANTAI, August 13, 2025 /PRNewswire/ — On August 13, Rongchang Biopharma (688331.SH/09995.HK) announced that its Phase III clinical study of tetasip, a world-first BLyS/APRIL dual-targeting fusion protein for the treatment of primary Sjögren's syndrome (pSS), achieved the primary endpoint as planned. Rongchang Biopharma will submit a marketing authorization application to the Center for Drug Evaluation (CDE) of the National Medical Products Admi…
Telitacicept Meets Primary Endpoint in Phase III Trial for Primary Sjögren's Syndrome in China
YANTAI, China, Aug. 13, 2025 /PRNewswire/ — On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III clinical trial for the treatment of primary Sjögren’s syndrome (pSS) in China, as per the pre-specified study protocol. The company will promptly submit a […]
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
